Cognitive & Behavioral Assessment

Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information

Philip S. Insel\textsuperscript{a,b,c,\*}, Sebastian Palmqvist\textsuperscript{a,d,e}, R. Scott Mackin\textsuperscript{b,f}, Rachel L. Nosheny\textsuperscript{b}, Oskar Hansson\textsuperscript{a,d}, Michael W. Weiner\textsuperscript{b,c}, Niklas Mattsson\textsuperscript{a,d,e}, and for the Alzheimer’s Disease Neuroimaging Initiative

\textsuperscript{a}Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden
\textsuperscript{b}Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA
\textsuperscript{c}Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
\textsuperscript{d}Memory Clinic, Skåne University Hospital, Malmö, Sweden
\textsuperscript{e}Department of Neurology, Skåne University Hospital, Lund, Sweden
\textsuperscript{f}Department of Psychiatry, University of California, San Francisco, CA, USA

Abstract

Introduction: Clinical trials in Alzheimer’s disease are aimed at early stages of disease, including preclinical Alzheimer’s disease. The high cost and time required to screen large numbers of participants for Aβ pathology impede the development of novel drugs. This study’s objective was to evaluate the extent to which inexpensive and easily obtainable information can reduce the number of screen failures by increasing the proportion of Aβ+ participants identified for screening.

Methods: We used random forest models to evaluate the positive predictive value of demographics, APOE, and longitudinal cognitive rates in the prediction of amyloid pathology, measured by florbetapir PET or cerebrospinal fluid.

Results: Predicting Aβ positivity with demographic, APOE, and cognitive information yielded a positive predictive value estimate of 0.65 (95% CI, 0.50–0.96), nearly a 60% increase over the reference Aβ+ prevalence in the cohort of 0.41.

Conclusions: By incorporating this procedure, clinical trial screening costs may be substantially reduced.

© 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Preclinical Alzheimer’s; Amyloid; Clinical trials; Cognition; APOE

1. Introduction

Dementia is one of the most debilitating consequences of aging, affecting not only patients but also families and caregivers. In 2010, 35.6 million people worldwide were estimated to have dementia, with care costing an estimated U.S. $604 billion [1]. Alzheimer’s disease (AD) is the most common cause of dementia, contributing to potentially 60%–70% of these cases. There are currently no approved treatments that slow the progression of AD, despite numerous clinical trials investigating potential disease-modifying therapies. A major obstacle for AD clinical trials is the high cost and time required to screen large numbers of candidate participants to meet specific trial inclusion criteria.

Because the accumulation of evidence suggesting the pathophysiological process of AD begins with β-amyloid (Aβ) deposition, many clinical trials have begun to require...
a substantial level of Aβ pathology for inclusion, with Aβ pathology measured by cerebrospinal fluid (CSF) biomarkers or positron emission tomography (PET) imaging [2]. However, measuring Aβ pathology with these technologies is expensive and invasive. This is especially an issue in trials using antiamyloid drugs directed against preclinical or prodromal AD, where evidence of Aβ pathology is essential to avoid diluting the drug effect by inclusion of individuals with normal Aβ levels (Aβ−). Clinical trials attempting to recruit cognitively healthy Aβ positive (Aβ+) elderly may expect large numbers of screen failures, given that the prevalence of Aβ positivity in cognitively healthy people aged 60–90 years is around 31%, as shown in a recent meta-analysis [3]. The overall goal of this study was therefore to provide tools to increase the proportion of Aβ+ participants identified for screening for trials of preclinical AD.

A global effort from organizations like the Brain Health Registry (www.brainhealthregistry.org), the Global Alzheimer’s Platform (globalalzplatform.org), and the European Prevention of Alzheimer’s Dementia Consortium (ep-ad.org) is underway to establish well-characterized trial-ready cohorts to expedite the screening process for AD clinical trials. Demographic, cognitive, and genetic information will be acquired both online and in clinics over time on large numbers of potential trial participants. Clinical trial recruiters will then be able to evaluate which participants may be likely to meet specific inclusion criteria before screening for specific trials. Recruiters may be able to exploit the associations between brain amyloid pathology and demographic [3–5], genetic [6–8], and cognitive [9–13] factors to improve the prediction of Aβ positivity. However, the degree to which these associations can improve the positive predictive value (PPV) in the forecasting of Aβ pathology in cognitively normal elderly is unknown. Therefore, the goal of this study was to quantify the effect of using demographic, cognitive, and genetic information in cognitively normal elderly to predict Aβ pathology, to reduce the number of screen failures and costs of clinical trials.

2. Methods

2.1. Participants

Data were obtained from the ADNI database (adni.loni.usc.edu). ADNI is the result of efforts of many co-investigators, and participants have been recruited from over 50 sites across the United States and Canada (see www.adni-info.org). The population in this study included ADNI-1 and ADNI-2 participants enrolled into the cognitively normal or subjective memory complaint cohorts. The key inclusion criteria that distinguish the subjective memory complaint cohort are a self-reported significant memory concern from the participant, quantified by using the Cognitive Change Index [14] and the Clinical Dementia Rating of zero. Participants had MMSE scores ≥ 24, were aged 55–90 years, were tested for CSF biomarkers or 18F-florbetapir PET, and were followed longitudinally for neuropsychological testing for at least 24 months.

2.2. CSF biomarker concentrations

Each CSF sample was collected by lumbar puncture and shipped on dry ice to the ADNI Biomarker Core laboratory at the University of Pennsylvania Medical Center for long-term storage at −80°C. Aβ positivity in CSF was determined by quantifying the 42-amino-acid isoform of Aβ1–42 (Aβ42) using the multiplex xMAP Luminex platform (Luminex Corp, Austin, TX) with the Research Use Only INNOBIA Alz-Bio3 kit (Fujirebio/Innogenetics, Ghent, Belgium) [15,16].

2.3. Florbetapir PET

Brain Aβ deposition was measured with PET using the ligand 18F-florbetapir. Methods to acquire and process ADNI florbetapir PET image data were described previously [10]. Mean florbetapir uptake from gray matter within lateral and medial frontal, anterior, and posterior cingulate, lateral parietal, and lateral temporal regions relative to uptake in the whole cerebellum (white and gray matter) was used as the florbetapir cortical mean for each participant. This measure was used to classify participants as Aβ+ or Aβ− as described below. Full details of acquisition and analysis can be found at http://adni.loni.usc.edu/methods/.

2.4. Cognitive outcomes

Cognitive measures assessed were the mini-mental state examination (MMSE), Alzheimer’s Disease Assessment Scale-cognitive subscale, 13-item version (ADAS13), immediate and delayed memory recall from the Wechsler Memory Scale-Revised (iMemory, dMemory), immediate and delayed Rey Auditory Verbal Learning Test (iAVLT, dAVLT), trail making test parts A and B (trails A & B), and category fluency [17–20].

2.5. Statistical analysis

The main analysis of this study was an evaluation of baseline demographics (age, gender, and education), APOE ε4 status (presence of at least one ε4 allele), baseline cognitive scores, and rates of change of cognitive scores over 24 months, for their ability to enrich a subsample for Aβ positivity. The main outcome was PPV, that is, the proportion of individuals predicted to be Aβ+ that were also observed to be Aβ+, for predictors assessed both individually and collectively. Aβ+ was defined as florbetapir PET SUVR > 1.10 [10] or CSF Aβ42 < 192 ng/L [15] in participants without florbetapir PET (n = 54). We classified subjects as Aβ+ if they became positive at any point during follow-up. This approach is based on evidence that if a subject is approaching amyloid positivity in the near term, that is, has emerging amyloid pathology, they are likely to have
increased atrophy rates [21], lower FDG PET, and subtle cognitive dysfunction and should not be included in the reference group [22]. Based on this evidence, several recent publications have suggested that current amyloid-positivity thresholds are likely too conservative [23,24]. Baseline characteristics of the Aβ groups were assessed using Wilcoxon rank-sum test for continuous variables and Fisher exact test for categorical variables.

In the assessment of individual predictors, continuous variables were iteratively thresholded, moving across the spectrum of the predictor, with the proportion of Aβ+ calculated at each threshold. The PPV estimates were then regressed on the range of thresholds using natural splines to produce PPV curves [25]. For the PPV curves of each predictor, 95% confidence intervals were estimated using the margins (2.5 and 97.5 percentiles) from 500 bootstrap samples.

The collective ability for the predictors to increase PPV was estimated using cross-validated random forests [26]. In each of 10 cross-validation folds, the probability of being Aβ+ was estimated for each participant by averaging over the votes from all decision trees. The probability threshold used to classify participants as Aβ+ was selected via cross-validation. For each candidate threshold, models were fit on the training sets (9 of the 10 folds) to get an estimate of mean PPV for 10 test sets. The threshold that maximized mean test set PPV was selected. For example, if the probability threshold $P = 0.70$ maximized the cross-validated estimate of PPV, then only participants whose estimated probability of being Aβ+ exceeded 0.70 were classified as Aβ+. The resulting 10 estimates from all folds were used to get a mean and 95% confidence interval for PPV using the 2.5th and 97.5th percentiles.

Cognitive tests were administered at baseline, month 6 (except logical memory), month 12, and month 24. Cognitive measures over 24 months were regressed on time from the baseline visit to estimate subject-specific cognitive rates of change using mixed-effects regression with a random intercept and slope and an unstructured covariance matrix for the random effects. By month 24, all cognitive tests had been assessed at 3 or more follow-up visits, allowing participant-specific rates to be estimated. $P$ values were all two sided and considered significant at the 0.05 level. All analyses were done in R v3.1.1 (www.r-project.org).

3. Results

There were 353 participants with complete data, including demographic, APOE, Aβ information, and 24-month follow-up. One-hundred forty-four participants (40.8%) were Aβ+ (119 measured by PET, 25 by CSF), and 209 (59.2%) were Aβ− (180 by PET, 29 by CSF). Aβ+ participants were older, less educated, and had a higher proportion of females and APOE e4 positivity, compared with Aβ− participants (Table 1). PPV curves for age and education are shown in Fig. 1.

Aβ+ participants had lower baseline cognitive scores compared to Aβ− participants on eight of the nine outcomes, five of which were significantly or marginally significantly lower. Cognitive differences are summarized in Table 2. PPV curves for individual baseline cognitive scores and 24-month rates are shown in Fig. 2.

Results of combinations of predictors are shown in Fig. 3. The best performing model included all variables: demographic, APOE, baseline cognition, and 24-month rates, yielding a PPV estimate of 0.65, nearly a 60% increase beyond the reference Aβ+ prevalence in the cohort of 0.41. Sixty participants were predicted to be Aβ+, of which 39 were actually positive. Participants predicted to be Aβ+ had a mean age of 78.1 years (range, 65–90 years), an

![Fig. 1. Positive predictive value (PPV) plots: age and education. Estimates of PPV (proportion of Aβ+) are plotted against continuous predictors, age and education. For age, the thresholds on the x-axis are more exclusive, with fewer participants included moving from right to left, that is, at age = 70 years, the estimate of the proportion of Aβ+’s is shown for individuals ≥70 years. For education, the thresholds are also more exclusive from right to left, that is, at education = 17 years, the estimate of the proportion of Aβ+’s is shown in individuals with ≤17 years of education. The gray shaded areas are 95% confidence intervals for the PPV estimates. The dashed black line is the reference PPV for the full cohort.](image-url)
average of 15.3 years of education (6–20 years) and were 51.7% female and 41.7% APOE ε4+. They had lower baseline cognitive scores and performed worse over time compared with the remainder of the cohort, which were not identified for increased risk of Aβ positivity. Cognitive scores and rates are summarized in Table 3.

4. Discussion

The main finding of this study is that prediction of β-amyloid pathology can be improved in a cognitively normal population without expensive and invasive procedures. Enriching recruitment of cognitively normal Aβ+ subjects is feasible through the use of demographic, cognitive, and genetic predictors, both individually (Figs. 1 and 2) and collectively (Fig. 3). A 0.65 proportion of Aβ-positivity, nearly 60% above the reference proportion of 0.41, was found when all predictors, including longitudinal cognitive rates, were modeled. If used for pre-screening in a clinical trial aimed at recruiting 1000 Aβ+ participants, this information could reduce the number of people undergoing biomarker screening from 2451 to 1539 participants. By

![Graphs showing individual predictor positive predicted value (PPV) curves: baseline cognition and 24-month rates. PPV curves are plotted against baseline cognitive thresholds in the left column and 24-month rate thresholds in the right column. Thresholds become more exclusive moving from the right to left, i.e. PPV estimates are shown for individuals with worse scores than the threshold given on the x-axis. The gray shaded areas are 95% confidence intervals for the PPV estimates. The dashed black line is the reference PPV for the full cohort. Abbreviations: dMemory, delayed memory recall; dAVLT, delayed A VLT.](image-url)
incorporating this procedure and using online cognitive testing, clinical trial screening costs of approximately $7500 USD per participant ($5000 for an Aβ PET scan and $2500 for an MRI, clinical/cognitive testing, EKG, and other laboratory measures; per written communication, Reisa Sperling, MD, 2016) may be reduced by nearly 7 million USD total, while decreasing the number of people undergoing invasive and time-consuming procedures by almost 40%. PET scan costs vary by country and are considerably greater in the United States compared with Europe [27]. Alternatively, measuring Aβ pathology by lumbar puncture would be markedly less expensive with screening costs around 1400 USD per participant in the United States and again considerably less in Europe (per personal written communication, Niklas Mattsson, MD, PhD, 2016).

The increase in the prevalence of Aβ positivity with age is well established [3–5]. In a large meta-analysis of cognitively normal participants, the prevalence of Aβ positivity increased from about 17% at age 60 years to 33% at age 80 years and up to 50% at age 95 years [3]. In our analysis, the proportion of Aβ+’s steadily increases with age until a plateau in the late 70s. However, the confidence intervals are wide at this end of the age range, and it is unlikely that the rate of Aβ positivity does not continue to increase. Age continues to be one of the strongest predictors of Aβ positivity.

The robust association between APOE ε4 genotype and β-amyloid pathology is also well established [6–8]. In this study, 58% of APOE ε4 carriers were Aβ+ compared to 34% of noncarriers. This risk increase is similar to the increase of 51% versus 23% shown in the AIBL cohort [3]. Just under 42% of the model-predicted Aβ+ participants in our study were APOE ε4+, resulting in a lower rate of APOE ε4 positivity compared with the full Aβ+ cohort. This low rate of APOE ε4 positivity among those predicted to be Aβ+ highlights the importance of the combination of predictors and not just a dependence on APOE genotype to enrich Aβ positivity. From a clinical trial

Fig. 3. Full model PPV estimates and 95% confidence intervals. PPV estimates and 95% confidence intervals are shown for seven different groups of predictors. When the 24-month rates are included, baseline (BL) cognition is also included. The vertical dashed black line in the reference PPV for the full cohort.
is a higher rate of AD in females [28,29], the slight episodic memory
findings observed in this study are less clear. Although there are no
differences in Aβ positivity in females observed in this study but was not seen in other large cohort studies [3,8]. However, once age, APOE genotype, and cognitive measures were included in the model, gender did not predict Aβ positivity. The ADNI cohort is also more educated than the general population, refraining from strict inclusion criteria such as APOE ε4 positivity will be important to avoid restrictive drug labeling.

The associations of gender and education with Aβ pathology observed in this study are less clear. Although there is a higher rate of AD in females [28,29], the slight increase in prevalence of Aβ positivity in females observed in this study was not seen in other large cohort studies [3,8]. However, once age, APOE status, and cognitive measures are included in the model, gender did not predict Aβ positivity. The ADNI cohort is also more educated than other cohorts, including population-based cohorts, which may contribute to the high overall rate of Aβ positivity in this sample, following from the cognitive reserve hypothesis and similar associations observed in other studies [30,31]. The additional slight increase in Aβ-positivity in individuals with fewer years of education is likely due to the small sample size of less educated individuals in ADNI.

Subtle cognitive dysfunction and increased rates of cognitive decline associated with Aβ-positivity in cognitively normal elderly have been replicated in many independent cohorts [9–13]. A meta-analysis comprising 34 independent studies of cognitively normal participants found overall significant associations between amyloid burden and poorer performance on measures of memory, executive function, and global cognition [13]. Given these associations, the increase in the proportion of Aβ+’s at the lower end of the spectrum of cognitive scores and rates observed in this analysis was expected. Increases in PPV are seen with a decrease in the cognitive scores and faster rates of decline in multiple domains (Fig. 2) not only delayed memory recall. It is possible that cognitive measures only marginally associated with Aβ positivity across the entire spectrum of scores in small samples may still be useful for increasing PPV if the concentration of Aβ+’s increases toward the bottom 20%–30% of scores. This is especially true if the rate of Aβ positivity accelerates at the low end of the spectrum, as it appears to do in several cognitive measures in Fig. 2. In large cohorts of thousands of participants, the bottom quartile of scores may represent a large pool from which to recruit into clinical trials. Cognitive measures provide important complementary information to demographics and APOE and greatly improve the precision of the prediction of Aβ pathology (Fig. 3).

A study of cognitively normal elderly from the Mayo Clinic Study of Aging [32] found the strongest predictors of Aβ pathology to be age, APOE status, family history of dementia, and/or AD, but not cross-sectional cognition and did not evaluate longitudinal cognitive change. Unfortunately, family history of AD was not assessed in our analysis because of the large proportion of missing data for family history, although it is possible or likely that family history information could further improve Aβ enrichment. In summary, the relationships reported in previous studies of Aβ, demographics, APOE, and cognitive data support the results of our model to predict Aβ pathology.

In Fig. 3, PPV estimates and confidence intervals are improved but not maximized when only subsets of the available predictors are modeled. It is not until all categories of predictors—demographic, genetic, and cognitive scores and rates—are included that PPV estimates reach 65% and confidence intervals narrow. This suggests that the prediction of Aβ pathology in cognitively normal elderly

### Table 3

| Variable               | Nonenriched (N = 293) | Aβ+ enriched (N = 60) |
|------------------------|------------------------|------------------------|
|                        | Mean (SD)              | Range                  | Mean (SD)              | Range                  |
| **Baseline cognition** |                        |                        |                        |                        |
| MMSE                   | 29.1 (1.11)            | 24–30                  | 28.9 (1.34)            | 24–30                  |
| ADAS13                 | 8.6 (3.96)             | 0–20                   | 12.2 (3.89)            | 1–24                   |
| dMemory                | 13.7 (3.13)            | 6–23                   | 11.1 (3.32)            | 5–19                   |
| iMemory                | 14.5 (3.03)            | 5–23                   | 11.9 (3.34)            | 3–21                   |
| dAVLT                  | 7.9 (3.88)             | 0–15                   | 5.6 (3.61)             | 0–15                   |
| iAVLT                  | 55.1 (12.57)           | 21–86                  | 45.6 (9.97)            | 23–74                  |
| Trails A               | 32.5 (9.72)            | 14–77                  | 41.0 (13.68)           | 22–90                  |
| Trails B               | 76.9 (34.47)           | 32–300                 | 113.6 (47.36)          | 51–251                 |
| Category fluency       | 21.0 (5.50)            | 6–38                   | 18.8 (5.01)            | 7–28                   |
| **24-month rates**     |                        |                        |                        |                        |
| MMSE                   | −0.05 (0.09)           | −0.54 to 0.05          | −0.12 (0.11)           | −0.40 to 0.03          |
| ADAS13                 | −0.27 (0.34)           | −0.94 to 1.19          | 0.13 (0.46)            | 0.07 to 1.33           |
| dMemory                | 0.32 (0.49)            | −1.15 to 1.58          | −0.29 (0.61)           | −1.32 to 1.49          |
| iMemory                | 0.49 (0.23)            | −0.21 to 1.10          | 0.24 (0.26)            | −0.25 to 1.07          |
| dAVLT                  | 0.30 (0.42)            | −1.37 to 1.50          | −0.04 (0.43)           | −1.00 to 1.17          |
| iAVLT                  | 1.16 (0.92)            | −1.55 to 4.20          | 0.33 (0.95)            | −1.99 to 3.06          |
| Trails A               | −0.89 (1.75)           | −5.01 to 14.26         | 0.24 (2.98)            | −6.85 to 16.37         |
| Trails B               | −0.84 (4.02)           | −23.22 to 17.36        | 3.62 (8.77)            | −16.24 to 33.90        |
| Category fluency       | 0.05 (0.42)            | −1.08 to 1.86          | −0.16 (0.47)           | −1.21 to 1.28          |
participants cannot be optimally done with simple independent thresholds for each predictor, but rather that risk must be evaluated with all predictors in concert. This can be seen by considering the range of characteristics of the predicted Aβ+ group from the best model, where less than half of these participants are APOE ε4+, many are aged <75 years, and some have memory or global cognitive scores above the median (Supplementary Table). Thus, whereas rates of Aβ positivity increase with age, declining cognitive scores and APOE ε4-positivity, the ability and precision to predict Aβ pathology increases substantially when these risk factors are assessed collectively. As such, clinical trials may benefit from using a set of interdependent inclusion criteria based on multiple factors.

This study has several limitations. The cognitive tests described here were administered in clinic. Whether online cognitive testing will predict Aβ positivity with the same PPV is unknown. The confidence intervals for the models shown in Fig. 3 overlap substantially. However, the best performing model has a lower confidence limit well above the reference PPV. A much larger cohort will be required to provide the power to test for model differences. The prevalence of Aβ positivity in the ADNI cohort of cognitively normal controls is also on the high end of the spectrum of previously reported estimates, calling into question how the methods developed here would perform in other cohorts [33]. This cohort is not population based and is more educated on average, making the relationships among predictors and amyloid pathology observed here potentially less generalizable to other cohorts due to cognitive reserve. The enrichment of Aβ pathology in this analysis relied on subtle cognitive dysfunction within the range considered to be cognitively normal. Identifying Aβ pathology in participants with high cognitive scores remains a challenge and will likely require the identification of further biomarkers associated with Aβ or downstream effects of Aβ pathology. Additionally, the random forest model known for its flexibility in terms of modeling nonlinearity and the interactions among predictors comes at the cost of the ability to report simple estimates of the relationship between the predictors and the response [26]. The effects of predictors in random forest models vary over hundreds of bootstrap resamples, precluding the report of a simple closed form solution to predict amyloid pathology. For this reason, results are summarized by PPV estimates and confidence intervals of subsets of predictors and also the range of characteristics of the predicted Aβ-pathology group. Nevertheless, even without specifying effects of individual predictors, a random forest model such as the one presented here is conceivable as a well-defined statistical working tool for pre-screening participants in clinical trials.

Finally, considerable improvements to the recruitment of cognitively normal elderly with Aβ pathology can be done without expensive or invasive procedures. By implementing a pre-screening procedure to participants enrolled in large online cohorts, the likelihood of Aβ pathology can be assessed and the number of screen failures due to biomarker inclusion criteria and associated costs reduced. When effective treatments for AD become available, a similar approach could be used to identify individuals likely to harbor Aβ pathology to inform decisions concerning treatment.

Acknowledgments

Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. This research was also supported by National Institutes of Health (NIH) grants P30 AG010129 and K01 AG030514, the European Research Council, the Swedish Research Council, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, the Swedish Alzheimer foundation, the Greta and Johan Kock Foundation for Medical Research, the Thelma Zoega foundation for medical research and the Swedish federal government under the ALF agreement. PSI had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.dadm.2016.07.002.
1. Systematic review: Clinical trials in Alzheimer’s disease are aimed at early stages of disease, including preclinical AD. The high cost and time required to screen large numbers of participants for Aβ pathology impedes the development of novel drugs. This study’s objective was to evaluate the extent to which inexpensive and easily obtainable information can reduce the number of screen failures by increasing the proportion of Aβ+ participants identified for screening.

2. Interpretation: In a cohort study of 353 subjects, predicting Aβ-positivity with demographic, APOE, baseline cognition and 24-month rates of cognitive change yielded a positive predicted value (PPV) estimate of 0.65 (95% CI, 0.50–0.96), nearly a 60% increase over the reference Aβ+ prevalence in the cohort of 0.41.

3. Future directions: By incorporating a β-amyloid prediction algorithm, clinical trial screening costs, recruitment time and the use of expensive, invasive procedures in trials of preclinical AD may be substantially reduced, thus accelerating the development of novel treatments for AD.

References

[1] World Health Organization. Dementia: a public health priority. Available at: http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed December 14, 2015.

[2] Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The Aβ4 study: stopping AD before symptoms begin? Sci Transl Med 2014;6:228fs13.

[3] Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015;313:1924–38.

[4] Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275–83.

[5] Clifford JR, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. Lancet Neuro 2014;13:997–1005.

[6] Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122–31.

[7] Clifford JR, Wiste HJ, Weigand SD, Knopman DS, Vemuri P, Mielke MM, et al. Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span. JAMA Neurol 2015;72:511–9.

[8] Pike KE, Ellis KA, Villemagne VL, Good N, Chetelat G, Arnes D, et al. Cognition and beta-amyloid in preclinical Alzheimer’s disease: data from the AIBL study. Neuropsychopharmacology 2011;40:2384–90.

[9] Insel PS, Mattsson N, Mackin RS, Kornak J, Nosheny R, Tosun, Turgut D, et al. Biomarkers and cognitive endpoints to optimize trials in Alzheimer’s disease. Ann Clin Transl Neurol 2015;2:534–47.

[10] Landau SM, Mintun MA, Joshi AD, Koepp RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578–86.

[11] Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology 2012;79:1636–44.

[12] Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, et al. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurol 2015;73:85–92.

[13] Heden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 2013;80:1341–8.

[14] Rattanabannakit C, Risacher SL, Gao S, Lane K, Brown SA, McDonald BC, et al. The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests. J Alzheimers Dis 2016;51:1145–59.

[15] Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s Disease Neuroimaging Initiative subjects. Ann Neurol 2009;65:403–13.

[16] Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of β-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336–45.

[17] Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 1958:8:271–6.

[18] Wechsler DA. Wechsler Adult Intelligence Scale–Revised. New York: Psychological Corporation; 1987.

[19] Rey A. L’examen clinique en psychologie. Paris: Presses Universitaires de France; 1964.

[20] Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–64.

[21] Insel P, Mattsson N, Donohue MC, Mackin RS, Aisen PS, Jack CR, et al. The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimers Dement 2014;10:PB37–8.

[22] Insel P, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, et al. Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Neurology 2016;86:1887–96.

[23] Mattsson N, Insel P, Nosheny R, Tosun D, Trojanowski JQ, Shaw LM, et al. Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol 2014:71:725–34.

[24] Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 2015;138:2020–33.

[25] Hastie TJ, Tibshirani RJ. Generalized additive models, vol. 43. London: CRC Press; 1990.

[26] Breiman L. Random forests. Mach Learn 2001;45:5–32.

[27] Hastie TJ, Tibshirani RJ. Generalized additive models, vol. 43. London: CRC Press; 1990.

[28] Breiman L. Random forests. Mach Learn 2001;45:5–32.

[29] Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H, et al. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 2015;36:297–309.

[30] Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 1998;55:809–15.

[31] Viña J, Lloret A. Why women have more Alzheimer’s disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis 2010;20 Suppl 2:S527–33.
[30] Stern Y, Alexander GE, Prohovnik I, Mayeux R. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer’s disease. Ann Neurol 1992;32:371–5.

[31] Alexander GE, Furey ML, Grady CL, Pietrini P, Brady DR, Mentis MJ, et al. Association of premorbid function with cerebral metabolism in Alzheimer’s disease: Implications for the reserve hypothesis. Am J Psychiatry 1997;154:165–72.

[32] Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Roberts RO, et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 2012;79:1570–7.

[33] Chételat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. Neuroimage Clin 2013;2:356–65.